HONG KONG, Oct. 16, 2023 /PRNewswire/ — Russell Reynolds Associates, a leading global leadership advisory and search firm, today announced that Sherman Leung has joined the firm as a Managing Director and Co-Head of RRA Greater China practice. Based in Hong Kong, Leung has an extensive background in international finance and investments across a range of management roles, which provides clients with insights into leadership solutions and talent strategy. With his multi-decades of banking and consulting experience across the Greater China region, Leung focuses on clients in financial services and professional services.

Sherman Leung

Prior to joining RRA, Leung spent more than 18 years at one of the largest global consulting firms where he was the Managing Partner and leader of Greater China Financial Services Consulting covering strategy, transformation, digital and technology, regulatory and compliance, risk management, and actuarial advisory. He was responsible for building growth across his portfolio, supported by 1400 professionals.  Before that, he also held different roles across top tier financial institutions.

"We are thrilled to have Sherman on board," said Grace Cheng, who leads the Greater China’s offices for Russell Reynolds Associates and member of the firm’s Board & CEO Advisory practice. "He will work closely with the team as we look to grow our advisory capabilities across Greater China. His wealth of experience and knowledge will be of real value to our team and our clients. His deep knowledge of the challenges our clients face in financial services is an advantage in identifying leadership solutions to achieve their business goals."

Leung received his Bachelor of Science Degree, major in computer science, and Master of Practicing Accounting from the University of Melbourne and Monash University respectively.  He is also a fellow of CPA Aust and a member of the HKICPA.

About Russell Reynolds Associates

Russell Reynolds Associates is a global leadership advisory firm. Our 600+ consultants in 47 offices work with public, private, and nonprofit organizations across all industries and regions. We help our clients build teams of transformational leaders who can meet today’s challenges and anticipate the digital, economic, sustainability, and political trends that are reshaping the global business environment. From helping boards with their structure, culture, and effectiveness to identifying, assessing and defining the best leadership for organizations, our teams bring their decades of expertise to help clients address their most complex leadership issues. We exist to improve the way the world is led. www.russellreynolds.com

Source : Russell Reynolds Associates Strengthens its Financial Services Practice in Greater China with Sherman Leung

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Pre-registration available in Philippines, Malaysia, Singapore, and Australia Diverse gameplay featuring 4v4 Realtime action PvP, roguelike dungeons, Minigames and more 

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ — Smilegate announced on the 11th that it will begin the Soft Launch Pre-registration of its new action adventure game "Wonderers: Eternal World" in 4 countries across the globe.

Smilegate, Wonderers Soft Launch Pre-registration Now Available

The 4 eligible countries will be the Philippines, Malaysia, Singapore, and Australia. Pre-registration will be available from the official website (https://wonderers.game.onstove.com), Google Play, and Apple App Store of the elibigle regions. Players who pre-register will receive up to $30’s worth of free giveaways, including Costumes, Dyes, Crystals and more.

Wonderers is a casual action battle game developed by NGELGAMES, the developers behind titles such as Hero Cantare and Tower of God: Great Journey. Wonderers supports both Mobile and PC Platforms.

Wonderers offers diverse gameplay through a variety of game modes. The signature mode, Gold Clash, is a 4v4 real-time team-based arena where players compete for victory by fighting for Gold generated on the map. Players can choose between closing out the game with the Gold they’ve collected or spending it to empower their characters, and as parts of the arena crumble over time, brawls will break out in the center of the map.

Wonderers also offers other modes for players who prefer a different style of play. The Glitch Dungeon is a PvE game mode with roguelike elements that can be enjoyed solo, and the open world offers various Minigames such as racing, board games, and fishing that can be enjoyed together with friends.

It’s also worth keeping an eye out for the cast of distinctive characters reimagined from their popular fairy-tale roots. Each character has their own set of skills and playstyles and that can be customized according to player preferences. The cute visuals add a layer of charm that bring the game’s themes to life.

Smilegate will roll out the soft launch of Wonderers in 4 countries this year. For more information on Wonderers, please visit the official Global Website. (https://wonderers.game.onstove.com).

Source : Smilegate, Wonderers Soft Launch Pre-registration Now Available

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SUZHOU, China, and ROCKVILLE, Md., Oct. 16, 2023 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration with AstraZeneca Investment (China) Co., Ltd. (or "AstraZeneca"). The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This global multi-center, randomized-controlled, open-label, pivotal Phase III confirmatory trial is designed evaluate the efficacy and safety of lisaftoclax combined with acalabrutinib versus immunochemotherapy in patients with treatment-naïve CLL/SLL.

This collaboration marks another step-forward in the joint clinical development of the lisaftoclax plus acalabrutinib combination by Ascentage Pharma and AstraZeneca. In June 2020, Ascentage Pharma entered into a clinical collaboration with Acerta Pharma, a research and development center of the AstraZeneca Group, to jointly conduct a global Phase II study designed to assess the safety, tolerability, and efficacy of lisaftoclax, Ascentage Pharma’s investigational Bcl-2 selective inhibitor, in combination with acalabrutinib, Acerta Pharma’s BTK inhibitor. In the study, lisaftoclax combined with acalabrutinib showed strong therapeutic potential, with an objective response rate (ORR) of 98% in patients with relapsed/refractory (R/R) CLL/SLL, an ORR of 100% in treatment-naïve patients with CLL/SLL, and an excellent safety profile that is on par with that of lisaftoclax monotherapy[1]. Those results were released as an Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting.

CLL/SLL is a hematologic malignancy caused by mature B-cell neoplasms. Primarily affecting older populations, CLL/SLL is among the most common leukemia subtypes in adults and accounts for a quarter of all leukemia cases in the Western World, with over 100,000 new diagnoses reported globally each year[2]. In China, CLL/SLL is occurring at a rapidly rising incidence rate, with a younger age of onset and higher aggressiveness[3], thus posing a serious threat to public health in the country. Advancements in basic research and targeted therapies have brought meaningful survival benefit to patients with CLL/SLL. However, CLL/SLL still presents major clinical challenges and urgent medical needs for new treatment options that can offer both efficacy and safety.

Lisaftoclax is a novel, orally administered small-molecule Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat malignancies by selectively blocking the antiapoptotic protein Bcl-2 and hence restoring the normal apoptosis process in cancer cells. With strong global best-in-class potential, lisaftoclax is the first Bcl-2 inhibitor in China and the second anywhere globally that has demonstrated compelling clinical activity and entered a pivotal registrational study. At present, lisaftoclax is being evaluated in multiple clinical studies across the world and more than 300 patients with CLL/SLL have already been treated with the drug. Interim results suggest that lisaftoclax, both as a monotherapy and in combination regimens, offers potent efficacy in patients with CLL/SLL and has the potential as a safer, more efficacious and more patient-friendly treatment option. It is also worth noting that in August 2023, lisaftoclax was cleared by the US Food and Drug Administration (FDA) to enter a global registrational Phase III study designed to assess the efficacy and safety of lisaftoclax combined with a BTK inhibitor in patients with CLL/SLL who have received prior therapies.

Acalabrutinib, a new generation highly selective BTK inhibitor that can specifically inhibit the BTK pathway, is a globally-adopted standard of care treatment for patients with CLL. In 2017, acalabrutinib was approved through the Priority Review process by the US Food and Drug Administration (FDA) for the second-line treatment of patients with mantle cell lymphoma (MCL), and subsequently in 2019, the drug was approved for the additional indication of adult patients with CLL/SLL. Meanwhile, acalabrutinib has been approved in more than 50 countries/regions, such as European Union and Japan until now. In China this year, acalabrutinib was sequentially approved for two indications that include patients with MCL who have received at least one prior therapy; and adult patients with CLL/SLL who have received at least one prior therapy.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "Combining Bcl-2 inhibitors and BTK inhibitors as a therapeutic approach has long attracted interest from both the research community and the industry. The Bcl-2 inhibitor lisaftoclax is a key drug candidate in Ascentage Pharma’s apoptosis-targeted pipeline. Results from the global Phase II study of lisaftoclax combined with acalabrutinib show that the combination regimen holds the promise as a patient-centric treatment strategy with enormous therapeutic potential. The clinical management of CLL/SLL overseas has already entered an era that is free of chemotherapies, and patients in China also desperately need a safer and more effective Bcl-2 inhibitor that can be combined with BTK inhibitors. Fulfilling our mission of addressing unmet clinical needs in China and around the world, we will work closely with AstraZeneca to actively advance this clinical development program of lisaftoclax and try to bring the drug to market as soon as possible for the benefit of more patients."

Ms. Haiying Yang, Vice President and Head of Medical Affairs at AstraZeneca China, commented, "Phase III results from the ASCENT, ELEVATE-TN, and ELEVATE-RR trials have solidified AstraZeneca’s position in the hematology field, while acalabrutinib-based combination regimens have been widely adopted as standard of care treatments. BTK inhibitors offer survival benefits to patients with lymphoma. However, there remains substantial clinical challenges in this therapeutic area and patients are in desperate need for new therapies that are both safe and efficacious, particularly fixed duration therapies. We are confident that acalabrutinib-based combinations can bring more effective and precision-targeting therapies to patients with hematologic malignancies in China as we take further steps in rendering hematologic malignancies into manageable chronic conditions. Through these innovative partnerships with local Chinese companies, we aspire to expand to more therapeutic areas and bring clinical benefit to a broader population of cancer patients in China."

References

[1] Davids M, Chanan-Khan A, Mudenda B, et al. Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study. Blood (2022) 140 (Supplement 1): 2326–2328.

[2] Yao, Y., Lin, X., Li, F. et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. BioMed Eng OnLine 21, 4 (2022). https://doi.org/10.1186/s12938-021-00973-6

[3] 刘澎. 复旦大学附属中山医院慢性淋巴细胞白细胞/小淋巴细胞淋巴瘤诊疗规范（v1.2018）[J].中国临床医学, 2018, 25(1).

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs, 2 FTDs, and 2 Rare Pediatric Disease (RPD) Designations from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Source : Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

GUANGZHOU, China, Oct. 16, 2023 /PRNewswire/ — Pantum, a leading provider of printing solutions specializing in the development, manufacturing, and distribution of laser printers and toner cartridges, is set to unveil its latest product offerings and cutting-edge innovations at its debut appearance in the 134th China Import and Export Fair(also known as the Canton Fair). The event commenced on October 15, 2023, in Guangzhou, China.

At present, Pantum has mastered complete technologies and products at all levels to fulfil various users’ needs. Pantum has a full range of products from entry level to high level, single function to multi-function, monochrome to color, a4 to a3, laser printers to extended products. At this Canton Fair, users will see Pantum’s changes in new products. 

As a brand making its first appearance at the Canton Fair, Pantum will feature two new highly efficient product series designed for simplicity and ease of use: the CM2100 series, a 20ppm A4 color laser printer series, and the BM2300 series, a 22ppm A4 monochrome laser printer series. Pantum is at booth B32-34 of Hall 6.1 at the Canton Fair Complex.

Pantum at the Canton Fair 1

Leon Zhang, Deputy Marketing Manager of Pantum, expressed, "The five-day Canton Fair as the most important exhibition in China, and the largest import and export trade show, has huge influence on a global scale. Participating in this influential international trade show provides Pantum with the opportunity not only to introduce our flagship products and brand strength to global buyers, but also is a key step as we accelerate our global market development. We hope to collaborate with partners both domestically and internationally to achieve mutual success."

The CM2100 series offers an unparalleled printing experience with outstanding color performance, boasting a printing speed of up to 20 pages per minute (ppm) for A4-sized paper. It also features the merge scan capability with ADF and Flatbed, enabling users to scan multi-page documents and compile them into a single document to improve working efficiency. The series is also compatible with ChromeOS, the Wi-Fi model supporting Bluetooth network configuration, and the ADF (automatic document feeder) model equipped with a 3.5-inch touchscreen.

Pantum at the Canton Fair 2

The BM2300 series, designed for ease of operation, offers driver-free installation for Win8.1/Win10/Win11 systems. The Wi-Fi model provides Bluetooth network configuration and supports 2.4G/5G dual-band Wi-Fi, along with the Pantum PiPMe Management Software.

In the meantime, Pantum is also highlighting two new monochrome high-speed laser printers at the Canton Fair, tailored for offices with exceptional efficiency and effortless operation. The BM5200 series sets new productivity standards with a rapid printing speed of up to 42ppm for A4 papers, Single-pass Duplex Scanning (DADF), FPOT of less than 5.9 seconds, and a maximum paper input capacity of up to 1,410 pages. The BM5200ADW model supports 2.4G/5G dual-band Wi-Fi, Bluetooth configuration, and the Pantum PiPMe Management Software.

The CM270ADN A3 color laser printer has a printing speed of 25ppm and supports auto duplex printing, copying, and scanning capabilities. It supports secure and confidential printing with direct scan or print from USB disk feature. The 7-inch color panel also enhances interaction to improve user experience.

Pantum’s showcase at the Canton Fair also includes a variety of color and monochrome laser printers for A3 and A4 with printing speeds ranging from 20 to 42ppm, as well as label printers and scanners.

Pantum at the Canton Fair 3

Pantum is always committed to introducing exciting new products catering to the needs of both enterprises and individual users. The company welcomes all guests to visit Pantum’s booth at the Canton Fair, and witness firsthand the cutting-edge technology and exceptional performance of its printers, label printers, and scanners. Stay tuned for more exciting developments from Pantum.

About Pantum

Founded in 2010, Pantum is a printer manufacturer with comprehensive portfolio covering printers, printing materials, and printing solutions and services. Since 2011, Pantum began its overseas expansion with a current global footprint of more than 110 countries. With its patented technology, Pantum is committed to meeting evolving printing needs by offering cost-effective, user-friendly, and energy-efficient products, along with reliable printing solutions. Today, Pantum continues to deliver enhanced value to its customers through its budget-friendly products and premium services.

For more information, please visit our website, Facebook, Instagram, and YouTube.

Source : Pantum Showcases Latest Product and Technology Innovation at 134th Canton Fair

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Pairs of Watches for Partners Evoke the Festive Look of Winter Illuminations

Also Worn by Five-Member South Korean Girl Group ITZY

TOKYO, Oct. 16, 2023 /PRNewswire/ — Casio Computer Co., Ltd. announced today the release of the latest addition to the G-SHOCK brand of shock-resistant watches. Seasonal Collection 2023 presents five new limited-edition models for the winter season, which can be worn in pairs by partners for a coordinated look. Featuring shining metallic-colored dials, the GM-2100WS, GM-S2100WS, GA-2100WS, GMA-S2100WS, and GA-110WS watches evoke the sparkling beauty of festive winter illuminations.

The five new shock-resistant timepieces making up this season’s lineup — the GM-2100WS, GM-S2100WS, GA-2100WS, GMA-S2100WS, and GA-110WS — feature dials treated with brilliant metallic vapor deposition in a charming array of hues inspired by the gorgeous look of festive decorations and illuminations brightening the streets of winter.

The diverse lineup includes a range of sizes, designs, and color schemes, offering the enjoyment of coordinating a paired fashion look with a romantic partner, friend, or family member. With colorful dials set off against both metal and resin bezels, the watch design features a base tone of white and forms modeled after the GA-2100, with its iconic octagonal bezel, and the GA-110, with its distinctive dimensional dial.

Featuring metal bezels and differing sizes, the GM-2100WS and GM-S2100WS present a cool, stylish look with their respective navy and pink dial colors.

The GA-2100WS, GMA-S2100WS, and GA-110WS feature resin bezels and showcase dials in vivid hues of blue, orange, or purple that shine with striking brilliance.

As a special design feature for a lineup of watches meant for pairing, an image of string looped and tied into a heart shape is engraved on the case back of each watch to express bonds or ties of connection with people near and dear.

A new promotional image features the five members of South Korean girl group ITZY proudly wearing all five models of the G-SHOCK Seasonal Collection 2023.

Source : Casio to Release G-SHOCK Watches with Shining Metallic-Colored Dials

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Oct. 16, 2023 /PRNewswire/ — Sozo Aesthetic Clinic is launching an updated acne scar treatment program for modern busy professionals in Singapore. Dr Justin Boey, Medical Director, explains more about acne scars treatments in Singapore. This program is a medically proven combination of procedures that removes acne scars permanently and successfully. Acne and acne scars is a problem for busy working professionals as it can be embarrassing.

Acne scars are depressions on the skin that can be permanent if not treated immediately and properly. While many ignore their acne scars, some people see it as a bothersome condition that contributes to reducing their self-esteem, especially if their jobs require them to look appealing at all times.

There are a lot of do-it-yourself acne scars treatments searchable on the internet – but not all are guaranteed safe and effective. Acne scars treatments vary on different individual’s skin. One remedy is sufficient for specific skin types, while to others, it provides more breakouts, which leads to more stubborn acne scars.

This Raffles Place clinic shared that one acne scar treatment is not enough to fully cure acne scars. "Acne Scars are challenging to improve, and sticking with one treatment is often inadequate. A lot of patients are unsatisfied with their acne scars treatment results."

"We recommend different methods based on our patient’s skin type and the extent of the scarring."

Sozo Aesthetic Clinic in Singapore has numerous acne scars treatments that are medically proven for all people struggling with it. Their upgraded acne scar treatment protocol for the year 2023 will target deep and stubborn facial acne scars using three proven therapies to treat the root cause of acne scars.

Firstly, the Subcision and Dermal Filler are either performed to make the appearance of scars shallower. The next step is Fractional RF Microneedling (INFINI), which is for deep skin remodelling. Lastly, the Fractional CO2 or Fractional Pico Laser is for superficial skin resurfacing that delivers tiny microthermal zones in the target areas.

"To perfect the skin even more, light touches of TCA cross chemical peel can be done to minimize those pores." Dr Justin Boey, Medical Director of Sozo Aesthetic Clinic, suggested.

About Sozo Aesthetic Clinic

Sozo Aesthetic Clinic is an aesthetic medical clinic in Singapore that serves patients from all over South-East Asia. They offer a comprehensive collection of Acne Scar treatments. Their services are featured in a lot of famous media outlets in Singapore.

Find them at
1 Raffles Place #05-12/13, Singapore 048616
Phone: 69351811
Website: https://sozoclinic.sg
Media contact: [email protected] 

Source : Sozo Aesthetic Clinic, Raffles Place in Singapore, Introduces Updated Scars Treatment Protocol

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Oct. 16, 2023 /PRNewswire/ — Heidrick & Struggles (Nasdaq: HSII), a premier provider of global leadership advisory and on-demand talent solutions, added one partner to its Executive Search business in Asia Pacific in September 2023.

Puneet Malhotra joined Heidrick & Struggles as a partner in the New Delhi office. A member of the Global Technology & Services practice, Puneet is a trusted advisor to global clients on executive-level talent solutions and succession planning. For nearly 20 years, he has worked across a range of C-suite mandates for technology, software, and professional services firms.

"Technology and services organizations must remain prepared and flexible as they scale their operations to meet the demands of a growing global market," said Stephen McAlinden, Regional Leader, Asia Pacific and the Middle East. "With a wealth of experience in succession planning and executive-level talent in the tech sector, Puneet brings a critical perspective to our clients on the leading edge of innovation and business transformation."

About Heidrick & Struggles
Heidrick & Struggles (Nasdaq: HSII) is a premier provider of global leadership advisory and on-demand talent solutions, serving the senior-level talent and consulting needs of the world’s top organizations. In our role as trusted leadership advisors, we partner with our clients to develop future-ready leaders and organizations, bringing together our services and offerings in executive search, diversity and inclusion, leadership assessment and development, organization and team acceleration, culture shaping and on-demand, independent talent solutions. Heidrick & Struggles pioneered the profession of executive search more than 70 years ago. Today, the firm provides integrated talent and human capital solutions to help our clients change the world, one leadership team at a time.® www.heidrick.com

Heidrick & Struggles Media Contact:
Lillian Lee
+852 2103 9389
[email protected]

Source : Heidrick & Struggles Adds Executive Search Partner in Asia Pacific

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network